Anheuser-Busch Inbev SA vs ResMed Inc. — how do they compare? Anheuser-Busch Inbev SA trades at $79.37 (market cap $153.27B), while ResMed Inc. trades at $193.41 (market cap $28.79B). The key difference: Anheuser-Busch Inbev SA is far larger — about 5.3× ResMed Inc.'s market cap, and Anheuser-Busch Inbev SA pays the higher dividend (1.7%). Which is the better fit depends on your goals.
| BUD | RMD | |
|---|---|---|
Market Cap | $153.27B | $28.79B |
Sector | Consumer Staples | Health |
52-Week High | $85.09 | $293.73 |
52-Week Low | $57.10 | $182.82 |
Enterprise Value | $214.46B | $27.98B |
Dividend Yield | 1.7% | 1.21% |
Trailing returns across standard periods
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →